Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Psyence Group Inc (OP: PSYGF )

0.0119 -0.0101 (-45.91%)
Streaming Delayed Price Updated: 1:44 PM EST, Nov 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Psyence Group Inc

Psychedelics Headlines: Anti-inflammatory Effects, Global Drug Survey, 'Synthetic Surprise,' UK's Harm Reduction Hub And More
Discover the latest research on psychedelics, from anti-inflammatory effects to end-of-life therapy. New journal issue and online course available. 
Via Benzinga
How To Finance A Psychedelics Business? Learn From These Four Companies
Clearmind Medicine Announces Pricing of $3.5 Million Public Offering 
Via Benzinga
Psyched: Australia As Psychedelics Hub, Advanced Scans Of Brain On DMT, New PAC For Congressional Influence, 9 States Advancing Bills & More
Australia: Enveric, FSD Pharma, Psyence & Others Advance Businesses 
Via Benzinga
Psychedelic Research Expands In Australia With Palliative Care Partnership & New MDMA Analog Portfolio
Psyence Partners with iNGENū for Palliative Care Clinical Trial 
Via Benzinga
Psychedelics Update: MDMA Export, 3D Farm, Recovery Center Reopens, Mushroom Extraction & E-Commerce
Health Canada Oks Clinical-Grade MDMA Export To UK Life sciences psychedelics company PharmAla Biotech Holdings Inc. and its manufacturing partners received a Health Canada export permit for no less... 
Via Benzinga
Psychedelics Travel: Clinical-Grade Magic Mushrooms Extract Exported From Southern Africa To UK
Lifesciences psychedelics biotech Psyence Group Inc. (OTCQB: PSYGF) recently exported purified pharmaceutical-grade psilocybin mushroom extract from its licensed and certified production facility in... 
Via Benzinga
6 Psychedelics Companies Take Action: Here Are The Latest, Major Announcements
Second week of 2023, and business is up and running. Let’s take a look at the announcements shared by some of the companies in the psychedelics space. 
Via Benzinga
Psyched: First Ayahuasca Pill Created, Psychedelics Legalization Predicted, UK's Research Support And More
Ayahuasca Pill Is Officially Here, Filament CEO Discusses Future Plans The first medical-grade drug candidate of the psychedelic ayahuasca is being developed. 
Via Benzinga
Psyence, Revive Therapeutics Ink Private Placements: Capital To Support Drug Trials
Life sciences biotech Psyence Group Inc. (OTCQB: PSYGF) has closed the second tranche of its previously announced private placement of up to $2.2 million (CA$3 million). 
Via Benzinga
Psychedelics Company Filament Signs Licensing Deal With Psyence In US, UK And EU
Filament Health Corp. (OTCQB: FLHLF) and Psyence Group Inc. (OTCQB: PSYGF) have inked a worldwide commercial licensing deal. 
Via Benzinga
European Psychedelics Research Group Nabs $2M In Seed Funding As Clinical Research Picks Up Speed
UK psychedelics clinical research organization Clerkenwell Health raised $2.047.710 (£2.1 million) in seed funding, bringing the total to date up to $2.437.750 (£2.5 million), all of which will be used... 
Via Benzinga
International Magic Mushrooms: Where Are They Produced And Where Are They Headed?
Psyence Group Inc. 
Via Benzinga
Psyched: Magic Mushrooms Vs. Psychotherapy, Psilocybin For Frontline Health Workers & Protecting Peyote
As a wave of news about psychedelics research and successful applications sweeps across the country and abroad, Psyched is back to wrap up the exciting movement of this rapidly evolving sector. 
Via Benzinga
Magic Mushrooms Vs. Psychotherapy For Incurable Cancer Diagnosis Moves Forward In UK Clinical Trials
UK's Medicines and Healthcare products Regulatory Agency (MHRA) approved Psyence Group Inc. 
Via Benzinga
Psyched: Big Pharma's Sanofi Enters Psychedelics Space, DNA From 80 Psilocybe Mushrooms Published Online, Maine Psychedelics Bill Shelved
Benzinga’s first-ever Psychedelics Capital Conference was a colossal success. Over 600 investors, policymakers, industry executives and thought leaders gathered at the Fontainebleau Hotel in Miami... 
Via Benzinga
Psyence, Filament Strike Magic Mushroom Product Licensing Agreement: What You Need To Know
Psyence Group (OTCQB: PSYGF) and Filament Health Corp. (OTCQB: FLHLF) announced the signing of a licensing agreement: Filament is to license its proprietary psilocybin derived drug, PEX010, and the... 
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.